Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results